GYRE Stock Analysis: Buy, Sell, or Hold?
GYRE - Gyre Therapeutics, Inc. Common Stock
$7.56
-0.11 (-1.43%)
▼
5d:
-2.2%
30d:
+10.53%
90d:
-5.85%
BUY
HIGH Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 08, 2026
8d
Get Alerted When GYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GYRE shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: GYRE shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: GYRE is currently trading at $7.56, which is considered fair relative to its 30-day fair value range of $7.02 to $7.79. From a valuation perspective, the stock is trading at a discount (Forward PE: -39.3) compared to its historical average (45.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GYRE is showing sideways momentum. The price is currently testing key support at $7.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GYRE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.67 (+143.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GYRE is showing sideways momentum. The price is currently testing key support at $7.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GYRE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.67 (+143.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.02 -
$7.79
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 143.4% below Wall St target ($18.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$7.02 -
$7.79
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$7.34
Resistance Level
$8.20
Current Trend
Sideways
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-39.33
Wall Street Target
$18.67
(+143.4%)
Revenue Growth (YoY)
33.4%
Earnings Growth (YoY)
166.2%
Profit Margin
4.3%
PE vs Historical
-39.3 vs 45.4
CHEAP
Share & Embed Analysis
Last updated: April 29, 2026 10:52 AM ET
Data refreshes hourly during market hours. Next update: 11:52 AM
Data refreshes hourly during market hours. Next update: 11:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 60 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 57 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$298 | 58 HOLD |
